Exact Sciences Corp. (EXAS) News
Filter EXAS News Items
EXAS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EXAS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest EXAS News From Around the Web
Below are the latest news stories about EXACT SCIENCES CORP that investors may wish to consider to help them evaluate EXAS as an investment opportunity.
Should Exact Sciences Stock Stay in Your Portfolio Right Now?EXAS' solid focus on expanding its lead Cologuard test and advancing new solutions bodes well for investors. |
Exact Sciences price target raised to $70 from $60 at Evercore ISIEvercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group. Published first on TheFly – t |
Exact Sciences to Participate in J.P. Morgan Healthcare ConferenceMADISON, Wis., January 02, 2025--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. |
Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report?Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Pacira (PCRX) Up 5.5% Since Last Earnings Report: Can It Continue?Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Exploring High Growth Tech Stocks in December 2024Over the last 7 days, the United States market has risen 1.4% and is up an impressive 34% over the last 12 months, with earnings expected to grow by 15% per annum in the coming years. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these favorable market conditions. |
Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)Editor’s note: The headline of this story was updated to correct an error related to the reported day of the week. On Monday, the Centers for Medicare & Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule. Included was a final decision related to CMS pricing for Exact Sciences Corp’s (NASDAQ:EXAS) Cologuard Plus, a second-generation test that received FDA approval in October. William Blair writes that the determinations effectively raise reimbursem |
Exact Sciences to Participate in December Investor ConferencesMADISON, Wis., November 26, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. |
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024MADISON, Wis., November 25, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium® (SABCS®) from December 10-13 in San Antonio, Texas. |
Exact Sciences Corporation (EXAS): Among the Best Genomics Stocks to Buy Right NowWe recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where Exact Sciences Corporation (NASDAQ:EXAS) stands against the other genomics stocks. Genomics is the study of genes and how they function. Many rapidly growing companies are emerging in the genomics […] |